NASH Drug Cost Concerns On Level With HCV Treatments For Payers

OptumRx, Harvard Pilgrim watching closely as Intercept’s Ocaliva nears market entry with claim for primary biliary cholangitis; use restrictions against off-label use in NASH are likely.